Last reviewed · How we verify
Dupilumab - Dose Reduction
Dupilumab - Dose Reduction is a IL-4 receptor antagonist monoclonal antibody Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps. Also known as: Dupixent.
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.
At a glance
| Generic name | Dupilumab - Dose Reduction |
|---|---|
| Also known as | Dupixent |
| Sponsor | Johns Hopkins University |
| Drug class | IL-4 receptor antagonist monoclonal antibody |
| Target | IL-4 receptor alpha (IL-4Rα) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammation. By blocking this receptor, it suppresses the production of IgE and inflammatory cytokines, reducing eosinophil recruitment and activation. This mechanism addresses the underlying pathophysiology of multiple type 2 inflammatory conditions including atopic dermatitis, asthma, and eosinophilic esophagitis.
Approved indications
- Moderate-to-severe atopic dermatitis
- Moderate-to-severe asthma with type 2 inflammation
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
- Pruritus
Common side effects
- Injection site reactions
- Conjunctivitis
- Headache
- Oropharyngeal pain
- Herpes simplex infection
Key clinical trials
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (PHASE3)
- Dupilumab De-escalation in Pediatric Atopic Dermatitis (PHASE4)
- Dupilumab Therapy in Nephrotic Syndrome in Children (PHASE2)
- DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema (PHASE4)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- Withdrawal of Dupilumab in Severe Asthma (PHASE4)
- Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab - Dose Reduction CI brief — competitive landscape report
- Dupilumab - Dose Reduction updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI
Frequently asked questions about Dupilumab - Dose Reduction
What is Dupilumab - Dose Reduction?
How does Dupilumab - Dose Reduction work?
What is Dupilumab - Dose Reduction used for?
Who makes Dupilumab - Dose Reduction?
Is Dupilumab - Dose Reduction also known as anything else?
What drug class is Dupilumab - Dose Reduction in?
What development phase is Dupilumab - Dose Reduction in?
What are the side effects of Dupilumab - Dose Reduction?
What does Dupilumab - Dose Reduction target?
Related
- Drug class: All IL-4 receptor antagonist monoclonal antibody drugs
- Target: All drugs targeting IL-4 receptor alpha (IL-4Rα)
- Manufacturer: Johns Hopkins University — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate-to-severe atopic dermatitis
- Indication: Drugs for Moderate-to-severe asthma with type 2 inflammation
- Indication: Drugs for Chronic rhinosinusitis with nasal polyps
- Also known as: Dupixent
- Compare: Dupilumab - Dose Reduction vs similar drugs
- Pricing: Dupilumab - Dose Reduction cost, discount & access